Our findings suggest that specific inhibition of TIM3 and TIGIT in NK cells, inhibition of PD1 in CD4+ Temra, and inhibition of TIGIT in CD8+ Temra could be promising strategies to advance NK and T cell-based immunotherapies in MM and its precursor stages. This evidence concerns the gene CD4 and Miyoshi myopathy.